PHATHOM PHARMACEUTICALS, INC. Investment Income, Interest
PHATHOM PHARMACEUTICALS, INC. (PHAT) reported Investment Income, Interest of $1.51 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeInterest · last filed 2026-07-30
- PHATHOM PHARMACEUTICALS, INC. investment income, interest for the quarter ending 2026-06-30 was $1.51M, a 15.50% decline year-over-year.
- PHATHOM PHARMACEUTICALS, INC. investment income, interest for the quarter ending 2026-03-31 was $1.74M, a 34.24% decline year-over-year.
- PHATHOM PHARMACEUTICALS, INC. investment income, interest for the quarter ending 2025-12-31 was $1.20M, a 65.70% decline year-over-year.
- PHATHOM PHARMACEUTICALS, INC. investment income, interest for the quarter ending 2025-09-30 was $1.41M, a 61.92% decline year-over-year.
- PHATHOM PHARMACEUTICALS, INC. investment income, interest for fiscal 2025 was $7.04M, a 53.53% decline from fiscal 2024.
- PHATHOM PHARMACEUTICALS, INC. investment income, interest for fiscal 2024 was $15.16M, a 92.46% increase from fiscal 2023.
- PHATHOM PHARMACEUTICALS, INC. investment income, interest for fiscal 2023 was $7.88M, a 269.42% increase from fiscal 2022.
- PHATHOM PHARMACEUTICALS, INC. investment income, interest for fiscal 2022 was $2.13M, a 5100.00% increase from fiscal 2021.
| Period end | Investment Income, Interest 3 month | Investment Income, Interest 6 month | Investment Income, Interest 9 month | Investment Income, Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.51M 10-Q · filed 2026-07-30 | $3.25M 10-Q · filed 2026-07-30 | $4.45M derived: sum of 3 quarters · filed 2026-07-30 | $5.86M derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | $1.74M 10-Q · filed 2026-04-30 | $2.94M derived: sum of 2 quarters · filed 2026-04-30 | $4.35M derived: sum of 3 quarters · filed 2026-04-30 | $6.14M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | $1.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $2.62M derived: sum of 2 quarters · filed 2026-02-26 | $4.40M derived: sum of 3 quarters · filed 2026-07-30 | $7.04M 10-K · filed 2026-02-26 |
| 2025-09-30 | $1.41M 10-Q · filed 2025-10-30 | $3.20M derived: sum of 2 quarters · filed 2026-07-30 | $5.84M 10-Q · filed 2025-10-30 | $9.35M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | $1.79M 10-Q · filed 2026-07-30 | $4.43M 10-Q · filed 2026-07-30 | $7.94M derived: sum of 3 quarters · filed 2026-07-30 | $11.65M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | $2.64M 10-Q · filed 2026-04-30 | $6.15M derived: sum of 2 quarters · filed 2026-04-30 | $9.86M derived: sum of 3 quarters · filed 2026-04-30 | $13.48M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $3.51M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $7.22M derived: sum of 2 quarters · filed 2026-02-26 | $10.85M derived: sum of 3 quarters · filed 2026-02-26 | $15.16M 10-K · filed 2026-02-26 |
| 2024-09-30 | $3.71M 10-Q · filed 2025-10-30 | $7.33M derived: sum of 2 quarters · filed 2025-10-30 | $11.65M 10-Q · filed 2025-10-30 | $15.00M derived: sum of 4 quarters · filed 2025-10-30 |
| 2024-06-30 | $3.62M 10-Q · filed 2025-08-07 | $7.94M 10-Q · filed 2025-08-07 | $11.29M derived: sum of 3 quarters · filed 2025-08-07 | $14.01M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $4.31M 10-Q · filed 2025-05-01 | $7.66M derived: sum of 2 quarters · filed 2025-05-01 | $10.38M derived: sum of 3 quarters · filed 2025-05-01 | $10.73M derived: sum of 4 quarters · filed 2025-05-01 |
| 2023-12-31 | $3.35M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $6.07M derived: sum of 2 quarters · filed 2025-03-06 | $6.42M derived: sum of 3 quarters · filed 2025-03-06 | $7.88M 10-K · filed 2025-03-06 |
| 2023-09-30 | $2.72M 10-Q · filed 2024-11-07 | $3.07M derived: sum of 2 quarters · filed 2024-11-07 | $4.53M 10-Q · filed 2024-11-07 | $5.82M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $348.00K 10-Q · filed 2024-08-08 | $1.81M 10-Q · filed 2024-08-08 | $3.10M derived: sum of 3 quarters · filed 2024-08-08 | $3.82M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $1.46M 10-Q/A · filed 2024-06-14 | $2.75M derived: sum of 2 quarters · filed 2024-06-14 | $3.47M derived: sum of 3 quarters · filed 2024-06-14 | $3.58M derived: sum of 4 quarters · filed 2024-06-14 |
| 2022-12-31 | $1.29M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-06-14 | $2.01M derived: sum of 2 quarters · filed 2024-06-14 | $2.13M derived: sum of 3 quarters · filed 2024-06-14 | $2.13M 10-K/A · filed 2024-06-14 |
| 2022-09-30 | $726.00K 10-Q · filed 2023-11-09 | $838.00K derived: sum of 2 quarters · filed 2023-11-09 | $845.00K 10-Q · filed 2023-11-09 | $851.00K derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $112.00K 10-Q · filed 2023-08-10 | $119.00K 10-Q · filed 2023-08-10 | $125.00K derived: sum of 3 quarters · filed 2023-08-10 | $133.00K derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $7.00K 10-Q · filed 2023-05-10 | $13.00K derived: sum of 2 quarters · filed 2023-05-10 | $21.00K derived: sum of 3 quarters · filed 2023-05-10 | $34.00K derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | $6.00K derived: 10-K 12 month − 10-Q/A 9 month · filed 2023-02-28 | $14.00K derived: sum of 2 quarters · filed 2023-02-28 | $27.00K derived: sum of 3 quarters · filed 2023-02-28 | $41.00K 10-K · filed 2023-02-28 |
| 2021-09-30 | $8.00K 10-Q/A · filed 2022-11-09 | $21.00K derived: sum of 2 quarters · filed 2022-11-09 | $35.00K 10-Q/A · filed 2022-11-09 | $51.00K derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $13.00K 10-Q · filed 2022-08-02 | $27.00K 10-Q · filed 2022-08-02 | $43.00K derived: sum of 3 quarters · filed 2022-08-02 | $58.00K derived: sum of 4 quarters · filed 2022-08-02 |
| 2021-03-31 | $14.00K 10-Q · filed 2022-05-10 | $30.00K derived: sum of 2 quarters · filed 2022-05-10 | $45.00K derived: sum of 3 quarters · filed 2022-05-10 | $227.00K derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | $16.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $31.00K derived: sum of 2 quarters · filed 2022-03-01 | $213.00K derived: sum of 3 quarters · filed 2022-03-01 | $1.09M 10-K · filed 2022-03-01 |
| 2020-09-30 | $15.00K 10-Q · filed 2021-11-08 | $197.00K derived: sum of 2 quarters · filed 2021-11-08 | $1.07M 10-Q · filed 2021-11-08 | $1.63M derived: sum of 4 quarters · filed 2021-11-08 |
| 2020-06-30 | $182.00K 10-Q · filed 2021-08-10 | $1.06M 10-Q · filed 2021-08-10 | $1.62M derived: sum of 3 quarters · filed 2021-08-10 | $2.05M derived: sum of 4 quarters · filed 2021-08-10 |
| 2020-03-31 | $878.00K 10-Q · filed 2021-05-11 | $1.44M derived: sum of 2 quarters · filed 2021-05-11 | $1.87M derived: sum of 3 quarters · filed 2021-05-11 | $1.97M derived: sum of 4 quarters · filed 2021-05-11 |
| 2019-12-31 | $559.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-30 | $988.00K derived: sum of 2 quarters · filed 2021-03-30 | $1.09M derived: sum of 3 quarters · filed 2021-03-30 | $1.09M 10-K · filed 2021-03-30 |
| 2019-09-30 | $429.00K 10-Q · filed 2020-11-10 | $530.00K derived: sum of 2 quarters · filed 2020-11-10 | $530.00K 10-Q · filed 2020-11-10 | |
| 2019-06-30 | $101.00K 10-Q · filed 2020-08-06 | $101.00K 10-Q · filed 2020-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 |